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Abstract: Using a specific 13C NMR localization method,
13C label incorporation into the glycogen C1 resonance
was measured while infusing [1-13C]glucose in intact rats.
The maximal concentration of [1-13C]glycogen was 5.1
6 0.6 mmol g21 (mean 6 SE, n 5 8). During the first 60
min of acute hyperglycemia, the rate of 13C label incor-
poration (synthase flux) was 2.3 6 0.7 mmol g21 h21
(mean 6 SE, n 5 9 rats), which was higher ( p , 0.01) than
the rate of 0.49 6 0.14 mmol g21 h21 measured $2 h
later. To assess whether the incorporation of 13C label
was due to turnover or net synthesis, the infusion was
continued in seven rats with unlabeled glucose. The rate
of 13C label decline (phosphorylase flux) was lower (0.33
6 0.10 mmol g21 h21) than the initial rate of label incor-
poration ( p , 0.01) and appeared to be independent of
the duration of the preceding infusion of [1-13C]glucose
( p . 0.05 for correlation). The results implied that net
glycogen synthesis of ;3 mmol g21 had occurred, similar
to previous reports. When infusing unlabeled glucose
before [1-13C]glucose in three studies, the rate of glyco-
gen C1 accumulation was 0.46 6 0.08 mmol g21 h21. The
results suggest that steady-state glycogen turnover rates
during hyperglycemia are ;1% of glucose consumption.
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It is well known that the brain is almost exclusively
dependent on blood glucose as the major source for ATP
synthesis in the brain (Siesjo¨, 1978). The brain maintains
a small glycogen reserve on the order of a few micro-
moles per gram, which provides the energy for a few
minutes of complete ischemia (Lowry et al., 1964; Swan-
son et al., 1989; Folbergrova´ et al., 1996). The small
cerebral glycogen concentration of 2–5 mmol g21 glu-
cosyl units reported in rodents (Nelson et al., 1968;
Strang and Bachelard, 1971; Sagar et al., 1987; Garriga
and Cusso, 1992) makes biochemical measurements
rather difficult. A previous study found that 2% of total
tissue radioactivity was detected in extracted glycogen
45 min after pulsed administration of the 2-deoxyglucose
(Nelson et al., 1984). Studies have suggested that brain
glycogen has an active metabolism that can be affected
by neuronal activity (Swanson, 1992), as well as by
hormones (Meguid et al., 1993) and several neurotrans-
mitters (Magistretti et al., 1986; Sorg and Magistretti,
1992). Recent studies using quantitative autoradiography
have shown that focal physiologic stimulation may lead
to cerebral glycogen breakdown (Swanson et al., 1992).
Global ischemia results in rapid glycogenolysis with near
complete depletion in a few minutes (Lowry et al., 1964;
Swanson et al., 1989; Folbergrova´ et al., 1996). Early
studies have suggested that brain glycogen can be mod-
ulated by hyperglycemia, barbiturate anesthesia, and hy-
perinsulinemia (Nelson et al., 1968). In summary, sub-
stantial evidence suggests that brain glycogen metabo-
lism may be controlled by several factors that may have
complex interactions (for review, see, e.g., Swanson,
1992).
Brain glycogen was shown in adult nervous tissue to
be localized to the glial compartment by many studies
(see, e.g., Wiesinger et al., 1997, and references therein),
and glycogen phosphorylase was shown to be exclu-
sively localized to glial cells (Pfeiffer et al., 1992).
Recent studies have shown a much higher similarity of
the genes expressing glycogen synthase (Pellegri et al.,
1996) and phosphorylase (Newgard et al., 1988) to the
genes expressing the corresponding isoenzymes in the
muscle than to the corresponding genes expressing the
liver isoenzymes. The structure of brain glycogen thus is
probably similar to that of muscle glycogen, which was
supported by structural studies (Chee et al., 1983).
To date, all methods used to assess brain glycogen
metabolism depend either on biochemical analysis or on
autoradiography of brain slices or on culture studies. The
limitations imposed by the rapid agonal changes in brain
glycogen content have been documented in the literature,
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and these limitations have been minimized to some ex-
tent using optimized extraction procedures, of which
microwave fixation reported the highest concentration
(Strang and Bachelard, 1971; Sagar et al., 1987; Garriga
and Cusso, 1992). As an alternative, glycogen metabo-
lism has been studied in astrocyte cultures (Wiesinger et
al., 1997, and references therein), but these model sys-
tems may not completely mimic the coupling of energy
metabolism between glia and neurons in vivo. Direct in
vivo measurement of brain glycogen is expected to pro-
vide further insight into the role glycogen plays in brain
metabolism. Of particular interest are noninvasive stud-
ies of glycogen in the human brain, of which very little
is known.
The glycogen C1 resonance can be reliably measured
noninvasively using natural abundance 13C NMR (Gru-
etter et al., 1991, 1994a; Taylor et al., 1992) in the
liver—where the glycogen concentration is on the order
of 100–500 mmol g21—and in the muscle—with a con-
centration of 30–100 mmol g21 (for review, see Shulman
et al., 1995). In contrast, the brain glycogen concentra-
tion is one to two orders of magnitude lower, which is
difficult to detect using natural-abundance 13C NMR. In
all 13C NMR studies of glycogen in the literature, full
three-dimensional localization has not been reported to
date. As an alternative, 1H NMR can potentially be used
to detect glycogen in vivo (Chen et al., 1994). A recent
report suggested that brain glycogen may be observable
in patients with McArdle’s disease (Salvan et al., 1997).
In a preliminary report we have shown that a distinct,
weak resonance at 5.35 ppm was observed in 1H NMR
spectra from a rat brain in vivo when using an echo time
of 1 ms, tentatively assigned to glycogen or potentially
overlapping free fatty acid signal (Tkac et al., 1999),
corresponding to a signal on the order of 1 mmol g21,
suggesting a low visibility in vivo.
According to the aforementioned studies measuring
radiolabel incorporation into brain glycogen, it should be
possible to enhance the sensitivity of 13C NMR by ob-
serving 13C label transfer into the small brain glycogen
pool with 13C-labeled glucose infusions. A completely
nondestructive approach required the elimination of the
signal from ;10-fold more concentrated muscle glyco-
gen present in superficial muscle tissue, which may over-
whelm the cerebral glycogen NMR signal. To overcome
this limitation, we specifically developed and optimized
a localization method suitable for brain glycogen detec-
tion. To assess further whether the observed label incor-
poration into brain glycogen reflects mostly isotope ex-
change (turnover) or net synthesis, the change in
[1-13C]glycogen was measured by switching the infusate
to unlabeled glucose (pulse–chase experiment) and by
reversing the order of label in the infusion (unlabeled
glucose followed by [13C]glucose). The purpose of this
study was (a) to evaluate whether 13C NMR can provide
a completely noninvasive measurement of brain glyco-
gen C1 signal, (b) to test under what circumstances 13C
NMR detection of brain glycogen metabolism is possible
in vivo, and (c) to attempt to characterize further in vivo
brain glycogen turnover.
MATERIALS AND METHODS
Animals
Fifteen male Sprague–Dawley rats (weighing 245 6 12 g,
mean 6 SE) were anesthetized with intravenous a-chloralose
administration with an initial dose of 40 mg/kg in the first hour
and a continuous infusion of 13.2 mg kg21 h21 thereafter. Rats
were ventilated at physiological conditions with a gas mixture
of 60%/40% O2/N2O after intubation. Arterial pH was main-
tained between 7.2 and 7.4 (7.35 6 0.02, mean 6 SE), and
arterial blood pressure and respiratory pressure were recorded
during the entire experimental time using AcqKnowledge
(Biopac Co., Santa Barbara, CA, U.S.A.). PaO2 was maintained
between 144 and 164 mm Hg, and, likewise, PaCO2 was main-
tained between 32 and 48 mm Hg (37 6 1.7 mm Hg). Oxygen
saturation was maintained .95% and continuously monitored
with an infrared sensor clipped to the tail (Nonin Medical,
Minneapolis, MN, U.S.A.). A rectal thermosensor (Cole-
Parmer, Vernon Hills, IL, U.S.A.) was used to verify that the
body temperature was at 37°C, which was maintained by plac-
ing the rats on a heated water blanket.
A femoral venous line was used for infusion of a 20%
(wt/vol) solution of D-[1-13C]glucose (Isotec, Miamisburg, OH,
U.S.A.), prepared as 70 or 100% 13C-enriched. To achieve
rapid 13C enrichment of plasma glucose, [1-13C]glucose was
administered according to previously published procedures
(Patlak and Pettigrew, 1976; Fitzpatrick et al., 1990; Terpstra et
al., 1998). The glucose infusion protocol was always as fol-
lows: A bolus of 0.8 mg (g wet wt)21 was administered in 1 ml
in the first 5 min, followed by a glucose infusion at 0.065 mg
min21 (g wet wt)21 rat for 20 min, which was dropped to 0.04
mg min21 (g wet wt)21 for the next 20 min, and then main-
tained at 0.03 mg min21 (g wet wt)21 thereafter. The initial
glucose administration was very similar to the one used previ-
ously, which we verified to yield modestly elevated, stable
arterial plasma glucose concentrations between 13 and 16 mM,
as illustrated by Terpstra et al. (1998). Similar infusion proto-
cols adapted to humans have been shown to produce rapid,
stable brain glucose 13C enrichment (Gruetter et al.,
1994b,1998a). The infusion protocol was used irrespective of
the presence of 13C label in the infused glucose solution.
Infusions of glucose were started 3 h after preparation of the
animals.
In vivo NMR methods
The NMR instrumentation was a Varian (Palo Alto, CA,
U.S.A.) INOVA spectrometer interfaced to a 31-cm horizontal
bore, 9.4-T magnet with an 11-cm actively shielded gradient
capable of switching 300 mT/m in 500 ms (Magnex Scientific,
Abingdon, U.K.). A quadrature 400-MHz 1H surface radiofre-
quency coil (14 mm in diameter, distributed capacitance) com-
bined with a linearly polarized, triple-turn 100-MHz 13C coil
with a diameter of 12 mm was used (Adriany and Gruetter,
1997). Shimming of all first- and second-order shim coils was
done with FASTMAP (Gruetter, 1993; Gruetter et al., 1998b),
typically resulting in 18–26 Hz linewidth of the water reso-
nance in a 9 3 5.5 3 12 mm3 voxel (;600 ml), which was
located on the midline and 1.5 mm posterior to the bregma.
Processing of 13C NMR spectra consisted of exponential mul-
tiplication (corresponding to a line broadening of 30 Hz), fast
Fourier transformation, baseline correction, and integration, all
of which were performed using built-in spectrometer software.
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With these processing parameters, the brain glycogen linewidth
was 87 6 10 Hz (mean 6 SD), which did not vary .10%
throughout each experiment.
To minimize contamination due to much more concentrated
glycogen in superficial muscle, we used outer volume suppres-
sion similar to previous reports (Shungu and Glickson, 1993;
Luo et al., 1995; Chen et al., 1997). The outer volume suppres-
sion pulses were a series of pulses of the hyperbolic secant type
(Tannus and Garwood, 1996) 2–8 ms in duration, used as either
(nonadiabatic) ;90° pulses or adiabatic 180° pulses with tim-
ing adjusted to minimize the glycogen signal in six slices
surrounding the volume of interest. In addition, an alternating
180° pulse with concomitant phase cycling (Ordidge et al.,
1986) was applied to localize the slice parallel to the carbon
surface coil. The excitation pulse was a 400-ms half-passage
pulse with tanh/tan modulation applied at 100.5 ppm, and the
detection frequency was placed between the signal of glycogen
C1 and the C1 of b-glucose.
Performance of the NMR pulse sequence used for localiza-
tion of glycogen signals was validated in two-compartment
phantoms consisting of a cylindrical tube 14 mm in diameter
containing a concentrated solution of glucose or myo-inositol
placed into a 24-mm-diameter cylindrical tube containing a 400
mM natural abundance oyster glycogen solution. The power of
the outer volume suppression pulses was calibrated relative to
the power needed to invert the 13C-labeled formic acid signal
from an external reference sphere placed at the 13C coil center.
WALTZ-16 decoupling (Shaka et al., 1983) in the proton
channel was applied during the entire acquisition time of 90 ms,
and decoupling power was ,3 W. The decoupler was gated to
0.1 W for generation of a nuclear Overhauser effect during the
recovery delay; the repetition time (TR) was 600 ms. A tem-
poral resolution of 1.5 or 3 min resulted from collecting the
data in either 128 or 256 scans per block, respectively, which
includes delays incurred from storing the data to disk. For some
of the data analysis, signal-to-noise was improved by coadding
the individual spectra.
Quantification of 13C-labeled glycogen C1 resonance
The 13C-labeled glycogen C1 resonance was quantified us-
ing the external reference method as in previous 13C magnetic
resonance spectroscopy measurements of muscle glycogen C1
in vivo (Gruetter et al., 1991; Taylor et al., 1992). This method
uses the comparison with an identical experiment performed on
a phantom solution of the same metabolite, which can be used
to calibrate the in vivo signal after suitable corrections for
loading. In brief, the effect of variable coil loading on sensi-
tivity was assessed by measuring the signal of the sphere placed
at the 13C coil center containing an aqueous solution of 13C-
labeled formic acid. In addition, the duration of a rectangular
180° pulse applied to the formic acid signal was measured,
which provided an independent assessment of coil loading
effects. Both measurements of coil loading effects on sensitiv-
ity were within 15% of each other. The [1-13C]glycogen signal
was quantified by performing the identical experiment on a
phantom containing ;400 mM natural abundance oyster gly-
cogen ([Glyc]o), taking into account the 1.1% natural abun-
dance of 13C. The external reference method for quantification
of the glycogen C1 signal was based on the following equation,
as in previous studies (Gruetter et al., 1991, 1994a; Taylor et
al., 1992):
@Glyc# 5
IGlycin vivo z IFAref z [Glyc]o z 0.011
IGlycref z IFAin vivo
(1)
where IGlyc denotes the integrated NMR signal of glycogen,
and IFA denotes that of formic acid measured from the phantom
reference experiment (ref) or measured from the rat brain (in
vivo). In one rat, the concentration was obtained by dividing
the [13C]glycogen signal by 0.7 to account for the lower en-
richment of 70% used for the [13C]glucose infusion. Equation
1 assumes that the saturation factors of glycogen are identical
in vivo and in solution, which was supported by the observation
that the T1 of in vivo glycogen was within 10% of that mea-
sured from oyster glycogen solutions and that the repetition
time used for the quantification was approximately two times
T1. The inversion recovery method was used to assess T1 for in
vivo glycogen in two rats, which was found to be 0.31 6 0.01 s,
and that for oyster glycogen was found to be 0.34 6 0.02 s,
both of which are in excellent agreement with previous reports
(Zang et al., 1990; Overloop et al., 1996).
Assessment of rate of 13C incorporation into
glycogen C1
Changes in glycogen C1 signal were assessed by the slope of
a linear regression of data points measured over a contiguous
60-min period. For these assessments, we pooled the time-
resolved data into 6-min spectra, which provided 10 time points
per slope determination. The median time was assigned to such
a measurement; hence, the synthase flux, Vsyn (rate of [1-13C]-
glycogen accumulation), measurement indicated with Vsyn (t
5 30) represents the slope measured over t 5 0–60 min, Vsyn
(t 5 90) represents the slope measured from 60 to 120 min, etc.
The nine experiments resulted in nine measurements of the rate
of glycogen C1 increase at t 5 30 after the start of [13C]glucose
administration. Because the slopes measured at t . 150 min
appeared to be independent of t (correlation coefficient r
5 20.04; p . 0.05), we averaged all 24 slope measurements
starting at 120 min, resulting in one rate value, denoted Vsyn (t
. 150).
When assuming that label incorporation into plasma glucose
is rapid compared with synthase flux, Vsyn, and phosphorylase
flux, Vphos (rate of [1-13C]glycogen breakdown during unla-
beled glucose infusions), and that turnover is the sole mecha-
nism by which label is incorporated into glycogen, the initial
rate of glycogen accumulation will be approximated by
d13Glyc1(t)
dt ’ Vsyn (2)
which slightly underestimates Vsyn. Conversely, when changing
the label from [1-13C]glucose to natural abundance glucose and
assuming that the 13C-labeled glucose is reduced to natural
abundance in a short time compared with Vphos, the initial rate
of glycogen signal decrease is given by
d13Glyc1(t)
dt ’ 2Vphos (3)
This approximation underestimates the true Vphos, if elimina-
tion of 13C label is not fast. For example, after 2 h, labeled
glucose was not further detectable, and a [1-13C]glycogen
concentration decrease of ;20% of the maximum was ob-
served (see Results). In this case, the rate of [1-13C]glycogen
decrease is given by
d13Glyc1(t)
dt ’ 20.8 Vphos (4)
i.e., the rates of brain glycogen degradation reported underes-
timate the flux through glycogen phosphorylase in vivo by
25%.
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For statistical tests, the two-tailed t test and Pearson’s rank
correlation test were used, where appropriate.
RESULTS
Throughout the study, physiological stability of the
rats was regularly monitored. As judged from the excel-
lent T2* of the water signal measured at 9.4 T throughout
each study, oxygenation of the brain was always ade-
quate, consistent with the low cerebral lactate, the high
glucose content, and the high phosphocreatine content
(Fig. 1). The observable tissue glucose resonances mea-
sured by 1H NMR spectroscopy (Fig. 1) as well as the
high 13C-labeled glucose signal observed by localized
13C NMR in all studies further indicated that substrate
delivery to the brain was adequate.
The following four experiments were carried out,
some sequentially on the same rat.
Validation of the localization method
A coronal magnetic resonance image of the rat brain
with a voxel position indicated by the rectangle is shown
in Fig. 2A. Clearly, substantial layers of skeletal muscle
tissue ascribed to the temporal jaw muscles can be dis-
cerned, and localization of the glycogen signal is there-
fore necessary.
The pulse sequence developed for three-dimensional
localization of the glycogen C1 signal was extensively
tested in phantom studies. Using various phantoms mim-
icking a 1–3-mm-thick muscle layer adjacent to the sur-
face coil, we verified that even when considering three
measurements that lasted 3 h each, signal from natural
abundance oyster glycogen (400 mM) in the outer cham-
ber was suppressed into the spectral noise. Phantom
studies were also used to verify the performance of the
localization with respect to voxel definition. The elimi-
nation of the phantom glycogen signal implied that a
fully labeled muscle glycogen signal corresponding to
;50 mM [13C]glycogen would be suppressed to the
noise level when measured in 4 min. The observation of
a glycogen C1 resonance with a signal-to-noise ratio of
;5:1 measured over 3 min was thus assumed to repre-
sent mainly brain glycogen. In addition, when placing
the spectrometer frequency at 30.5 ppm to minimize the
FIG. 2. 13C NMR spectroscopy of rat brain 20 min after cardiac
arrest (global ischemia). A: A coronal image acquired using the
FLASH sequence (TR 5 10 ms, TE 5 5 ms). The box indicates
the location of the voxel selected (9 3 5.5 mm). The small sphere
filled with 13C-labeled formic acid placed at the carbon coil
center can be seen at the top. B: The top trace shows a spec-
trum acquired without any localization means. The bottom trace
shows a spectrum acquired from a 560-ml volume. The two
spectra shown were acquired in an interleaved fashion simulta-
neously over 57 min by alternating blocks of 40-s unlocalized
measurements (64 scans) with 5-min blocks of localized mea-
surements (512 scans) and by separately adding the data in the
computer. Acquisition was started 20 min after initiating global
ischemia. Both spectra were processed with an exponential
multiplication (30 Hz line broadening) and are shown without
baseline correction. C: Horizontal stack plot of localized spectra
that were acquired with a 1.5-min temporal resolution from the
same rat. KCl was administered at t 5 0 min. The small arrows
indicate the resonance position of glycogen C1 (100.5 ppm).
Exponential multiplication (50 Hz line broadening) was applied.
FIG. 1. 1H NMR spectroscopy of rat brain. The 1H NMR spec-
trum was acquired as described elsewhere (Tkac et al., 1999). In
brief, a stimulated echo sequence with a seven-pulse water
suppression scheme was used (2-ms echo time, 5-ms mixing
time, 4-s repetition time, 320 scans, 100-ml volume). Processing
consisted of moderate Gaussian resolution enhancement and
fast Fourier transformation. Resonances from phosphocreatine
(PCr; arrow), glucose (Glc; arrow), and lactate (Lac; arrow) were
discernible among resonances from myo-inositol (Ins), taurine
(Tau), choline (Cho), creatine (Cr), glutamate (Glu), glutamine
(Gln), and N-acetylaspartate (NAA). PCr was within normal limits,
and the low Lac signal of ;10% of NAA implied a normal brain
Lac concentration of ;1 mmol g21.
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chemical shift displacement error, we noted that even
during long accumulations, the intense lipid–(CH2)n–
peak at 30.5 ppm due to the superficial fat was com-
pletely suppressed (data not shown), further supporting
the accuracy and reliability of the localization method.
To further validate the in vivo localization method, we
exploited the difference in agonal breakdown of muscle
glycogen (on the order of hours) compared with brain
glycogen, which has been reported to be on the order of
minutes (Lowry et al., 1964; Swanson et al., 1989). After
infusing 13C-labeled glucose for at least 3 h, KCl was
administered intravenously to induce cardiac arrest. In
spectra collected without the three-dimensional localiza-
tion method, we consistently observed glycogen and
glucose signals, as illustrated in Fig. 2B. The spectra
shown in Fig. 2B were acquired over a 57-min period
without localization, interleaved with the localization
turned on, starting 20 min after intravenous administra-
tion of KCl. Without three-dimensional localization of
the NMR signals (top), the detected 13C glycogen C1
signal is the sum of the signals originating from the
muscle as well as from the brain. With localization
(bottom), this signal completely vanished, confirming
that the method efficiently suppresses the noncerebral
glycogen C1 signal. Concomitant elimination of the ex-
tracerebral glucose signal also indicated adequate local-
ization efficiency for the glucose C1 signals.
Finally, we assessed whether the localized 13C signal
was consistent with brain glycogen by measuring the
time elapsed until the brain glycogen signal was elimi-
nated after intravenous injection of KCl. These measure-
ments were performed with a 90 s temporal resolution
after [1-13C]glucose was infused for at least 4 h (n 5 6
rats, four of which were part of experimental group II).
The glycogen intensity was reduced to 50% of the signal
recorded before KCl administration within 1.8 6 0.1 min
(mean 6 SE). After 15 6 3 min, the glycogen C1 signal
was reduced to ,10%. Such a rapidly decreasing glyco-
gen signal is illustrated in Fig. 2C. When averaged over
all postmortem measurements, the first spectrum ac-
quired after injection of KCl was reduced to 44 6 4%
(mean 6 SE). The concurrent decrease in 13C-labeled
FIG. 3. Time-resolved observation of label incorpo-
ration into cerebral brain glycogen. A: A stack plot of
13C spectra acquired over a 16-h experiment from
one rat. At t 5 0, the infusion of [1-13C]glucose was
started and after 8.5 h (indicated by the arrow) re-
placed with unlabeled glucose (pulse–chase exper-
iment). Processing consisted of exponential multipli-
cation (30 Hz line broadening), and the spectra are
shown without baseline correction. B: A horizontal
stack plot of the glycogen C1 resonance at 100.5
ppm from the same experiment shown in A. C: The
corresponding time course of the integrated glyco-
gen C1 resonance (F; left scale) and the integrated
b-glucose C1 resonance (E; right scale). The time
between 6.5 and 8 h was used for determination of
the T1 of glycogen C1 in vivo and 1H magnetic
resonance spectrum collection (similar to Fig. 1). For
easier visualization, the spectra used for this plot
were pooled to reduce the time resolution to 18 min
(by averaging the higher temporal resolution data).
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glucose signal was consistent with that observed by 1H
NMR spectroscopy after KCl administration (authors’
unpublished data) and reflect the well-known changes in
agonal glucose consumption.
Assessment of rate of 13C incorporation into
glycogen C1 (synthase flux)
The duration of [1-13C]glucose infusion, Tinf, before
continuing the infusion with unlabeled glucose (see ex-
perimental group III) was 10 (n 5 1 rat), 30 (n 5 1), 70
(n 5 1), 120 (n 5 1), 240 (n 5 2), 330 (n 5 1), and 550
min (n 5 2). All measurements were quantified using the
external reference method (based on Eq. 1) just before
the end of [13C]glucose infusion. When [1-13C] glucose
was infused for at least 30 min, the peak [1-13C]glycogen
concentration was 5.1 6 0.6 mmol g21 glucosyl units
(mean 6 SE, n 5 8 rats).
Label incorporation into glycogen C1 was initially
faster and appeared to level off with infusion time, as
illustrated in Fig. 3A and B for one rat, for which glucose
was infused for 8.5 h. Figure 3C plots the quantified 13C
label in glycogen C1 as a function of time after the start
of 13C glucose infusion. Good reproducibility was im-
plied by the observation that the uncorrected NMR sig-
nal from six rats measured with Tinf . 240 min was
highly consistent with a coefficient of interindividual
variation of 18% (data not shown).
During the first 60 min of [1-13C]glucose infusion, the
rate of 13C-labeled glycogen accumulation assessed as
described in Materials and Methods [Vsyn (t 5 30) in Fig.
4] was almost fivefold higher (2.3 6 0.7 mmol g21 h21;
n 5 9) and remained higher for the first 90 min ( p
, 0.01) than that measured $2 h after the start of the
infusion (0.49 6 0.14 mmol g21 h21), indicated by Vsyn
(t . 150) in Fig. 4. The 24 measurements that were used
for calculating Vsyn (t . 150) did not show a correlation
with time as judged from the low correlation coefficient
(r 5 20.04, p . 0.05).
Assessment of [1-13C]glycogen decrease during
unlabeled glucose infusions (phosphorylase flux)
To determine whether the change in the apparent rate
of [1-13C]glycogen accumulation such as the one shown
in Fig. 3 can be ascribed entirely to turnover (when brain
glycogen synthesis and breakdown rates are similar), we
switched the infusate to unlabeled glucose after Tinf
minutes (n 5 7 rats). This was done with the same
infusion protocol (but by switching from labeled to un-
labeled glucose) in all of the experiments described in
Assessment of rate of 13C incorporation into glycogen
C1 (synthase flux), except for three cases (n 5 6). In an
additional study, 13C-labeled glucose was infused for
only 3 min (half-bolus) (n 5 1). The rate of glycogen C1
decrease, denoted Vphos, was measured as described in
Materials and Methods for at least the following 3 h. In
these experiments, the simultaneously detected, localized
glucose signals were reduced to ,10% of the initial
value within 2 h after the start of the unlabeled glucose
infusion. When the glucose signals were no longer de-
tectable by localized in vivo NMR, the brain glycogen
signal was 80 6 4% of the maximum, suggesting that
glycogen was still highly enriched with 13C-labeled glu-
cosyl units. During further infusion of unlabeled glucose,
the glycogen C1 signal remained remarkably stable, as
can also be seen from the stack plot (Fig. 3A). The
glycogen C1 resonance is shown in the horizontal stack
plot (Fig. 3B), and the time course of the integrated
resonance is plotted in Fig. 3C. The average rate of
[1-13C]glycogen decrease during natural abundance glu-
cose infusions was 0.33 6 0.10 mmol g21 h21 (mean
6 SE). Because the change in the glycogen signal was
assessed over intervals of 60 min each, the extended
times that were measured in the seven rats resulted in 39
rate assessments. Pooling the measurements of glycogen
decrease during the first 120 min after starting the unla-
beled glucose infusion into one data set (n 5 18 rate
assessments) and the remaining measurements into a
second measurement (n 5 21) showed that the rates were
not different (0.38 6 0.19 vs. 0.29 6 0.09 mmol g21 h21,
respectively; p . 0.05). The rate of glycogen degrada-
tion was also independent of the duration of the preced-
ing infusion of labeled glucose, Tinf (r 5 0.25, p . 0.05),
e.g., even when infusing only the first half of the bolus
(0.12 g of glucose per rat), the brain [1-13C]glycogen
concentration of 0.25 mmol g21 resulted in a signal that
was detectable 30 min after the start of the glucose
infusion and that remained detectable for .2 h. Like-
wise, when the glucose infusion was switched from
13C-labeled to unlabeled glucose after 10 min (0.2 g of
FIG. 4. Rate of brain [1-13C]glycogen changes during glucose
infusions. The solid columns indicate the rate of glycogen signal
change (determined by calculating the slope of a linear regres-
sion over a 60-min interval, as described in Materials and Meth-
ods) during infusion of [1-13C]glucose (Vsyn), measured at t 5 30
(n 5 9 measurements from n 5 9 rats), 60 (n 5 9), 90 (n 5 9), and
120 min (n 5 9). The fifth column indicates Vsyn measured at t
. 150 min (n 5 24 measurements). The hatched column (phos-
phorylase flux, Vphos) indicates the rate of [1-13C]glycogen de-
crease after the infusion was changed to unlabeled glucose (n
5 39, experimental group III) in seven rats. The stippled column
indicates the rate of [1-13C]glycogen increase, Vresyn, after pro-
longed periods of unlabeled glucose infusions (n 5 20 from three
rats, experimental group IV). Data are mean 6 SE (bars) values.
*p , 0.01 with a two-tailed t test versus Vsyn (t . 150).
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glucose per rat), [1-13C]glycogen increased to 0.55 mmol
g21, which remained detectable for the next 4 h. Vphos
did not show a correlation with Tinf (r 5 20.25, p
. 0.05).
Assessment of [1-13C]glycogen accumulation after
preceding hyperglycemia
To ascertain the degree by which the 13C label incor-
poration curves might reflect glycogen turnover rather
than net glycogen accumulation, we started the infusion
using the same infusion protocol in three rats, by first
infusing unlabeled glucose for at least 4 h, which was
then switched to [1-13C]glucose, and the rate of [1-13C]-
glycogen synthesis after preceding unlabeled glucose
infusion (Vresyn) was measured as described in Materials
and Methods. The rate of brain [1-13C]glycogen accu-
mulation was measured over at least 3 h, resulting in n
5 20 rate assessments, from which Vresyn in Fig. 4 was
calculated at 0.46 6 0.08 mmol g21 h21 (mean 6 SE).
This rate of [13C]glycogen accumulation after prolonged
hyperglycemia did not show a correlation with time (r
5 0.15, p . 0.05 for correlation).
DISCUSSION
Validation of the localization method
The rapid decrease of 13C-labeled glycogen C1 signal
observed postmortem (Fig. 2C) was consistent with the
majority of the localized signal being in vivo from brain
glycogen, because postmortem muscle glycogenolysis is
much slower. The rate of 13C-labeled glucose decrease
was as fast and consistent with 1H observations of the
total glucose content (authors’ unpublished data). We
observed a slightly slower rate of glycogen degradation
during global ischemia than what has been reported
(Lowry et al., 1964; Swanson et al., 1989). However, the
first spectrum acquired after injection of KCl was re-
duced to 44% of the initial value, ruling out major
contributions from muscle glycogen to the signal. A
factor that might have contributed to the slightly slower
rate of brain glycogen breakdown was the finite time of
1–2 min that elapsed between injection of KCl and
complete global brain ischemia.
Quantification of 13C-labeled glycogen C1
accumulation
Published literature values for total glycogen content
in the rat cortex range between 2 and 6 mmol g21
glucosyl units, assuming 12.5% protein content in brain
(Strang and Bachelard, 1971; Sagar et al., 1987; Garriga
and Cusso, 1992). The 5.1 mmol g21 13C-labeled brain
glycogen C1 observed after several hours is consistent
with these published values. However, under conditions
of infusing 13C-labeled glucose, the measured 13C label
in glycogen only represents total glycogen content if net
synthesis or breakdown is 0 and all glucosyl units have
been turned over. This may not be the case during
hyperglycemia, which has been shown to lead to modest
increases in brain glycogen content, and concentrations
approaching 10 mmol g21 have been reported in the rat
brain (Nelson et al., 1968). Assuming a turnover rate of
0.5 6 0.14 mmol g21 h21 based on the values of Vsyn (t
. 150) shown in Fig. 4, label incorporation due to
turnover was estimated to be 2.0 6 0.6 mmol g21 over
4 h, and net glycogen synthesis was estimated at 3.1
6 0.8 mmol g21. When assuming a glycogen concentra-
tion of ;5 mmol g21 (Sagar et al., 1987), a modest 60%
increase in brain glycogen is calculated, which is in good
agreement with the observations in unanesthetized brain
reported by Nelson et al. (1968).
Assessment of glycogen turnover rates during
glucose infusions
The rate of 13C incorporation into glycogen C1 was
initially higher and decreased with Tinf. In contrast, the
rate of 13C-labeled glycogen C1 decrease (Vphos in Fig.
4) during subsequent unlabeled glucose infusions did
not correlate with the duration of the unlabeled glu-
cose infusion or the duration of the preceding
[13C]glucose infusion. Because the label washout from
glycogen was (a) very slow and (b) not a function of
time or of the time of the preceding labeled glucose
infusion, an initial rate was observed. This supports
our assertion that after prolonged glucose infusions,
glycogen turnover is very slow. The rapid initial label
incorporation is consistent with a study showing rapid
activation of synthase and inactivation of phosphory-
lase after glucose loading (Cummins et al., 1983). The
stability of the glycogen C1 signal implied that brain
glycogen turnover was slow (;0.5 mmol g21 h21),
and Vsyn (t . 150) ; Vphos ; Vresyn (Fig. 4) implied
that net glycogen synthesis was minimal after a few
hours. The glycogen turnover rates and the initial
glycogen C1 synthesis rates observed in this study
were on the order of 30 –150 times slower than the rate
of glucose consumption of ;0.8 mmol g21 min21 in
the resting rat brain (Ueki et al., 1992) and imply a
stable brain glycogen pool in the unstimulated, lightly
anesthetized rat brain during glucose infusions.
A potential confounding factor can be the rate of
change in the fractional enrichment of the precursor
glucose being different between the initial [13C]glucose
administration and the subsequent unlabeled glucose in-
fusion. These differences were estimated to have a neg-
ligible impact on these calculations of rate changes,
because the rate of glucose disappearance after switching
to unlabeled glucose infusions was fast compared with
the rate of glycogen breakdown: When the glucose sig-
nals were no longer detectable by localized in vivo
NMR, the brain glycogen signal was still 80% of the
peak observed 13C concentration, suggesting that glyco-
gen was still highly enriched with 13C-labeled glucosyl
units. The labeled glycogen pool should decrease with
;0.8 Vsyn (t 5 30), if Vsyn 5 Vphos, which was clearly not
the case for brain glycogen in the present study, which
suggests that although turnover on the order of 0.5 mmol
g21 h21 was present, it was slow and unlikely to account
completely for the rapid initial rise in brain [1-13C]gly-
cogen.
J. Neurochem., Vol. 73, No. 3, 1999
1306 I.-Y. CHOI ET AL.
Incorporation of deoxyglucose into brain glycogen 45
min after a pulse of 14C-labeled deoxyglucose has been
assessed to contain 2% of total tissue radioactivity, with
the majority of label trapped in the nonmetabolizable
2-deoxyglucose-6-phosphate (Nelson et al., 1984). Our
results support the notion that short administrations of
labeled glucose lead to minor amounts of the label in-
corporated into brain glycogen.
The hyperglycemia present in our experiment most
likely resulted in concomitant hyperinsulinemia,
which results in profound glycogen accumulation in
astrocyte cultures (Swanson and Choi, 1993, and ref-
erences therein).
To what extent the activity of gluconeogenesis re-
ported in astrocyte cultures (Schmoll et al., 1995) is also
present in vivo remains to be determined. In our exper-
iments, label scrambling at the triose phosphate level
(from the C1 to the C6 position and vice versa) leads to
an underestimation of the rate of glycogen synthesis.
We conclude that intravenous [13C]glucose infusion
results in a slow but efficient labeling of the astrocytic
glycogen. The new, completely noninvasive NMR meth-
ods we have developed for this purpose can be readily
extended to study human brain glycogen metabolism,
which should lead to a much-improved understanding of
the regulation of cerebral glycogen metabolism at rest
during hypoglycemia and during functional activation.
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